Clinical trials: Patients Take Medicine
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work.
- Trial name
- NCT06280235
- Testing
- BI 1569912
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication Adherence
Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Adherence to tyrosine kinase inhibitors is associated with improved outcomes in chronic myeloid leukemia patients. Hence, improved adherence might improve CML patients' prognosis.
- Trial name
- TAKE-IT (NCT01768689)
- Testing
- Adherence-encouraging interventions - Group meeting, Adherence-encouraging interventions - Individual meetings, Adherence-encouraging interventions - Monthly phone calls
- Where
- 4 sites in Israel
- Volunteers
- 58 people
- Sponsor
- pia raanani
Glaucoma
Observational Study of How Patients Take Eye Drops
This study is interested in monitoring how patients take eye drops, both through video-recordings and adherence monitoring, as well as their perceptions about their eye medications; including the dosing schedules, instillation…
- Trial name
- NCT00750646
- Testing
- MEMS cap
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Robin, Alan L., M.D.
Diabetes Mellitus, Type 2
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
- Trial name
- EDCOS (NCT04098575)
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 9,571 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study.
- Trial name
- NCT04937829
- Testing
- 5 mg BI 1569912, 20 mg BI 1569912
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Oncologic Disorders
Collaborative Network to Take Responsibility for Oral Anticancer Therapy 2
In 2015, the research team of KU Leuven and UGent started a pilot project supported by Kom op Tegen Kanker, called CONTACT-1. This multicentre before-after study aims at developing, implementing and evaluating a care pathway for…
- Trial name
- CONTACT-2 (NCT04142463)
- Testing
- Care pathway
- Where
- 10 sites in Belgium
- Volunteers
- 500 people
- Sponsor
- Ilyse Kenis
HIV Infections
The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine
To evaluate the pharmacokinetics, safety, and tolerance of delavirdine mesylate ( U-90152 ) after multiple doses given orally to asymptomatic HIV-1 positive patients who are maintained on a stable dose of zidovudine ( AZT ).
- Trial name
- NCT00002312
- Testing
- Delavirdine mesylate, Zidovudine
- Where
- United States
- Sponsor
- Pharmacia and Upjohn